CFRA cuts GlaxoSmithKline stock price target to $40, maintains hold
CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...
GSK Up Over 7%, On Track for Largest Percent Increase Since December 2022 — Data Talk
--On pace for largest percent increase since Dec. 6, 2022, when it rose 7.85% --Down 51.37% from its all-time closing high of $76.92 on Jan. 6, 1999 ...
GSK outlines 2025 growth driven by specialty medicines and new product launches
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...
FiercePharma7h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Top Stock Price Prediction: Strong Tailwinds On Nvidia, GSK, TSCM Stocks
Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...
Top Stock Price Prediction: Sentiment and Earnings Propel Nvidia, GSK, TSCM Stocks
Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...
Annual core operating profit increases for British pharma GSK
Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...
GlaxoSmithKline (GSK) Gets a Hold from UBS
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...
GSK shares rise over 5% after Q4 results
GlaxoSmithKline plc (NYSE: NYSE:GSK) shares gained 5.65% after the pharmaceutical giant reported fourth quarter revenue that beat analyst estimates, despite earnings falling short of expectations.
GSK lifts long-term sales targets on new drug pipeline
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Investing11h
European stocks steady; Santander soars after record profits
Santander (BME: SAN) stock soared over 6% after the Spanish lender reported record annual profits for the third consecutive ...